Lerociclib

Lerociclib (G1T38) is an oral CDK4/6 inhibitor used mainly for treating Hormone Receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer, especially after progression on prior endocrine therapy, often combined with fulvestrant to arrest the cell cycle and slow tumor growth. It works by blocking CDK4/6 proteins, preventing cancer cell proliferation with a generally good safety profile, showing significant progression-free survival benefits in clinical trials like LEONARDA-1, and offering a new option for endocrine-resistant cases. It is grouped under the following drug class(es): CDK4/6 Inhibitors. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Lerociclibum and G1T-38. Its PubChem CID is 86269224.

CAS No 1628256-23-4
Molecular Formula C26H34N8O
Molecular Weight 474.60 g/mol
Synonyms 4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one

Frequently Asked Questions